The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells

Giulia Gobbi, Benedetta Donati, Italo Faria Do Valle, Francesca Reggiani, Federica Torricelli, Daniel Remondini, Gastone Castellani, Davide Carlo Ambrosetti, Alessia Ciarrocchi, Valentina Sancisi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Inhibitors of BET proteins (BETi) are anti-cancer drugs that have shown efficacy in pre-clinical settings and are currently in clinical trials for different types of cancer, including non-small cell lung cancer (NSCLC). Currently, no predictive biomarker is available to identify patients that may benefit from this treatment. To uncover the mechanisms of resistance to BETi, we performed a genome-scale CRISPR/Cas9 screening in lung cancer cells. We identified three Hippo pathway genes, LATS2, TAOK1, and NF2, as key determinants for sensitivity to BETi. The knockout of these genes induces resistance to BETi, by promoting TAZ nuclear localization and transcriptional activity. Conversely, TAZ expression promotes resistance to these drugs. We also showed that TAZ, YAP, and their partner TEAD are direct targets of BRD4 and that treatment with BETi downregulates their expression. Noticeably, molecular alterations in one or more of these genes are present in a large fraction of NSCLC patients and TAZ amplification or overexpression correlates with a worse outcome in lung adenocarcinoma. Our data define the central role of Hippo pathway in mediating resistance to BETi and provide a rationale for using BETi to counter-act YAP/TAZ-mediated pro-oncogenic activity.

Original languageEnglish
JournalOncogene
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Lung Neoplasms
Proteins
Non-Small Cell Lung Carcinoma
Clustered Regularly Interspaced Short Palindromic Repeats
Gene Knockout Techniques
Drug Resistance
Genes
Neoplasms
Down-Regulation
Biomarkers
Clinical Trials
Genome
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Gobbi, G., Donati, B., Do Valle, I. F., Reggiani, F., Torricelli, F., Remondini, D., ... Sancisi, V. (Accepted/In press). The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells. Oncogene. https://doi.org/10.1038/s41388-019-0924-1

The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells. / Gobbi, Giulia; Donati, Benedetta; Do Valle, Italo Faria; Reggiani, Francesca; Torricelli, Federica; Remondini, Daniel; Castellani, Gastone; Ambrosetti, Davide Carlo; Ciarrocchi, Alessia; Sancisi, Valentina.

In: Oncogene, 01.01.2019.

Research output: Contribution to journalArticle

Gobbi, G, Donati, B, Do Valle, IF, Reggiani, F, Torricelli, F, Remondini, D, Castellani, G, Ambrosetti, DC, Ciarrocchi, A & Sancisi, V 2019, 'The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells', Oncogene. https://doi.org/10.1038/s41388-019-0924-1
Gobbi G, Donati B, Do Valle IF, Reggiani F, Torricelli F, Remondini D et al. The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells. Oncogene. 2019 Jan 1. https://doi.org/10.1038/s41388-019-0924-1
Gobbi, Giulia ; Donati, Benedetta ; Do Valle, Italo Faria ; Reggiani, Francesca ; Torricelli, Federica ; Remondini, Daniel ; Castellani, Gastone ; Ambrosetti, Davide Carlo ; Ciarrocchi, Alessia ; Sancisi, Valentina. / The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells. In: Oncogene. 2019.
@article{a0b413cf697649f6b44c862625c64c44,
title = "The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells",
abstract = "Inhibitors of BET proteins (BETi) are anti-cancer drugs that have shown efficacy in pre-clinical settings and are currently in clinical trials for different types of cancer, including non-small cell lung cancer (NSCLC). Currently, no predictive biomarker is available to identify patients that may benefit from this treatment. To uncover the mechanisms of resistance to BETi, we performed a genome-scale CRISPR/Cas9 screening in lung cancer cells. We identified three Hippo pathway genes, LATS2, TAOK1, and NF2, as key determinants for sensitivity to BETi. The knockout of these genes induces resistance to BETi, by promoting TAZ nuclear localization and transcriptional activity. Conversely, TAZ expression promotes resistance to these drugs. We also showed that TAZ, YAP, and their partner TEAD are direct targets of BRD4 and that treatment with BETi downregulates their expression. Noticeably, molecular alterations in one or more of these genes are present in a large fraction of NSCLC patients and TAZ amplification or overexpression correlates with a worse outcome in lung adenocarcinoma. Our data define the central role of Hippo pathway in mediating resistance to BETi and provide a rationale for using BETi to counter-act YAP/TAZ-mediated pro-oncogenic activity.",
author = "Giulia Gobbi and Benedetta Donati and {Do Valle}, {Italo Faria} and Francesca Reggiani and Federica Torricelli and Daniel Remondini and Gastone Castellani and Ambrosetti, {Davide Carlo} and Alessia Ciarrocchi and Valentina Sancisi",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41388-019-0924-1",
language = "English",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells

AU - Gobbi, Giulia

AU - Donati, Benedetta

AU - Do Valle, Italo Faria

AU - Reggiani, Francesca

AU - Torricelli, Federica

AU - Remondini, Daniel

AU - Castellani, Gastone

AU - Ambrosetti, Davide Carlo

AU - Ciarrocchi, Alessia

AU - Sancisi, Valentina

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Inhibitors of BET proteins (BETi) are anti-cancer drugs that have shown efficacy in pre-clinical settings and are currently in clinical trials for different types of cancer, including non-small cell lung cancer (NSCLC). Currently, no predictive biomarker is available to identify patients that may benefit from this treatment. To uncover the mechanisms of resistance to BETi, we performed a genome-scale CRISPR/Cas9 screening in lung cancer cells. We identified three Hippo pathway genes, LATS2, TAOK1, and NF2, as key determinants for sensitivity to BETi. The knockout of these genes induces resistance to BETi, by promoting TAZ nuclear localization and transcriptional activity. Conversely, TAZ expression promotes resistance to these drugs. We also showed that TAZ, YAP, and their partner TEAD are direct targets of BRD4 and that treatment with BETi downregulates their expression. Noticeably, molecular alterations in one or more of these genes are present in a large fraction of NSCLC patients and TAZ amplification or overexpression correlates with a worse outcome in lung adenocarcinoma. Our data define the central role of Hippo pathway in mediating resistance to BETi and provide a rationale for using BETi to counter-act YAP/TAZ-mediated pro-oncogenic activity.

AB - Inhibitors of BET proteins (BETi) are anti-cancer drugs that have shown efficacy in pre-clinical settings and are currently in clinical trials for different types of cancer, including non-small cell lung cancer (NSCLC). Currently, no predictive biomarker is available to identify patients that may benefit from this treatment. To uncover the mechanisms of resistance to BETi, we performed a genome-scale CRISPR/Cas9 screening in lung cancer cells. We identified three Hippo pathway genes, LATS2, TAOK1, and NF2, as key determinants for sensitivity to BETi. The knockout of these genes induces resistance to BETi, by promoting TAZ nuclear localization and transcriptional activity. Conversely, TAZ expression promotes resistance to these drugs. We also showed that TAZ, YAP, and their partner TEAD are direct targets of BRD4 and that treatment with BETi downregulates their expression. Noticeably, molecular alterations in one or more of these genes are present in a large fraction of NSCLC patients and TAZ amplification or overexpression correlates with a worse outcome in lung adenocarcinoma. Our data define the central role of Hippo pathway in mediating resistance to BETi and provide a rationale for using BETi to counter-act YAP/TAZ-mediated pro-oncogenic activity.

UR - http://www.scopus.com/inward/record.url?scp=85070827189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070827189&partnerID=8YFLogxK

U2 - 10.1038/s41388-019-0924-1

DO - 10.1038/s41388-019-0924-1

M3 - Article

AN - SCOPUS:85070827189

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -